Galectin Therapeutics Inc., of Norcross, Ga., reported that a preclinical study in a mouse model of non-alcoholic steatohepatitis (NASH), or fatty liver disease, demonstrated that oral administration of the company's lead galectin-3 inhibitor, GR-MD-02, resulted in significant disease improvement.